Evidence map›Paper›PMID 26931669›Full record

ArticleEuropean journal of clinical nutrition2016

Plasma levels of marine n-3 fatty acids and cardiovascular risk markers in renal transplant recipients.

I A Eide, D O Dahle, M Svensson, A Hartmann, A Åsberg, K S Bjerve, J H Christensen, E B Schmidt, M E Lauritsen, K Lund and 1 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical nutrition, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 17 citations in OpenAlex.

  1. The Effect of MarineNutrients · 2019
    Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

I A EideSection of Nephrology, Department Transplant Medicine, Oslo University Hospital, Oslo, Norway.
D O DahleSection of Nephrology, Department Transplant Medicine, Oslo University Hospital, Oslo, Norway.
M SvenssonDepartment of Renal Medicine, Akershus University Hospital, Lørenskog, Norway.
A HartmannSection of Nephrology, Department Transplant Medicine, Oslo University Hospital, Oslo, Norway.
A ÅsbergSection of Nephrology, Department Transplant Medicine, Oslo University Hospital, Oslo, Norway.
K S BjerveDepartment of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, Norway.
J H ChristensenDepartment of Nephrology, Aalborg University Hospital, Aalborg, Denmark.
E B SchmidtDepartment of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
M E LauritsenSection of Nephrology, Department Transplant Medicine, Oslo University Hospital, Oslo, Norway.
K LundSection of Nephrology, Department Transplant Medicine, Oslo University Hospital, Oslo, Norway.
T JenssenSection of Nephrology, Department Transplant Medicine, Oslo University Hospital, Oslo, Norway.
Oslo University Hospital · NOAalborg University Hospital · DKAkershus University Hospital · NONorwegian University of Science and Technology · NOUiT The Arctic University of Norway · NOUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesCardiovascular (CV) disease is the leading cause of death after renal transplantation. Marine n-3 polyunsaturated fatty acids (PUFAs) exert potential cardio-protective metabolic effects and might reduce CV morbidity and mortality in renal transplant recipients (RTRs). SUBJECTS/

methodsIn this cross-sectional study of 1990 Norwegian RTRs, transplanted between 1999 and 2011, associations between plasma phospholipid marine n-3 PUFA levels and various CV risk markers at 10 weeks after transplant were evaluated.

resultsHigher plasma marine n-3 PUFA levels were associated with lower resting heart rate (rHR), lower fasting plasma glucose (fPG) levels, lower plasma triglyceride levels and higher plasma high-density lipoprotein (HDL) cholesterol levels. Plasma levels of eicosapentaenoic acid, but not docosahexaenoic acid, showed a positive association with plasma HDL cholesterol levels. Plasma marine n-3 PUFA levels were not associated with plasma low-density lipoprotein cholesterol levels, pulse wave velocity or systolic and diastolic blood pressure. A negative association between plasma marine n-3 PUFA levels and CV mortality was weakened by additional adjustment for plasma triglyceride levels and rHR. The ratio of n-6 to n-3 PUFAs showed similar associations with CV risk markers as absolute plasma marine n-3 PUFA levels.

conclusionsThis is the first study in RTRs showing that marine n-3 PUFAs are negatively associated with rHR and fPG in addition to beneficial effects on plasma HDL cholesterol and triglyceride levels. Especially, effects on autonomic nervous function and triglyceride metabolism might contribute to explain the lower CV mortality risk with higher plasma marine n-3 PUFA levels previously shown in this cohort.

Indexed as

AdultBlood GlucoseBlood PressureCardiovascular DiseasesCholesterol, HDLCohort StudiesCross-Sectional StudiesDietDietary FatsFatty Acids, Omega-3FemaleFish OilsHeart RateHumansKidneyKidney TransplantationBlood GlucoseCholesterol, HDLDietary FatsFatty Acids, Omega-3Fish OilsPhospholipidsTriglycerides

Identifiers

PMID26931669
OpenAlexW2291664506

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.